Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company developing therapies focused on unmet medical needs across dermatology, oncology, neurology, and immunology. The company's pipeline includes HT-001, a topical formulation in Phase II trials for treatment of tyrosine kinase inhibitor-induced rashes and skin disorders; HT-KIT for mast cell-derived cancers and anaphylaxis; HT-TBI for traumatic brain injury and ischemic stroke; and HT-ALZ for Alzheimer's disease and neuroinflammatory conditions. Additional programs include HT-004 for asthma and allergies via inhalational administration, the BioLexa Platform in Phase I development for eczema, and HT-005 for lupus treatment.

The company operates through licensing and collaboration agreements with academic and research institutions, including George Washington University, North Carolina State University, the University of Cincinnati, and private biotechnology firms including Chelexa BioSciences, Zylö Therapeutics, and Voltron Therapeutics. These arrangements provide access to drug compounds and intellectual property supporting the company's pipeline development.

Hoth Therapeutics operates with minimal staffing, maintaining a two-person full-time employee base while headquartered in New York, New York. The company was incorporated in Nevada in 2017 and is listed on the Nasdaq exchange.